Madhusudhan Pamganamamula, MD
Internal Medicine · Odessa, TXNPI 1699743187
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (53.4%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 21 manufacturers reported payments, led by Amgen at 54.2% of the total. Reporting peaked in 2021 at $4,500 and has fallen 91.9% since, to $366 in 2025. Among internal medicine clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 101 payments — averaging $76.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$4K
- Biohaven Pharmaceuticals, Inc.$2K
- AbbVie$526
- Astellas Pharma US Inc$195
- Novo Nordisk$172
- Harmony Biosciences LLC$168
- plus $889 from 15 others
Across 27 payments — averaging $2362.61 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$41K
- Amgen$23K
What the payments were for
- Consulting fees$1,20016%
- Speaking & faculty fees$4,11353%
- Travel & lodging$3965%
- Food & beverage$1,75623%
- Education$2303%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 7 | $4,172 |
| Biohaven Pharmaceuticals, Inc. | 2 | $1,573 |
| AbbVie(2 entities) | 26 | $526 |
| Astellas Pharma US Inc | 6 | $195 |
| Novo Nordisk | 10 | $172 |
| Harmony Biosciences LLC | 4 | $168 |
| Novartis | 8 | $166 |
| Abbott | 5 | $112 |
| GSK | 6 | $103 |
| Pfizer | 6 | $102 |
| AstraZeneca | 5 | $92 |
| Phathom Pharmaceuticals, Inc. | 4 | $86 |
| Axsome Therapeutics, Inc. | 3 | $57 |
| Lilly USA, LLC | 2 | $38 |
| Jazz Pharmaceuticals Inc. | 1 | $29 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $21 |
| Sanofi-aventis U.S. LLC | 1 | $20 |
| Lundbeck LLC | 1 | $20 |
| Exact Sciences | 1 | $16 |
| Medtronic | 1 | $14 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Repatha$2,100
- AIMOVIG$2,013
- NURTEC ODT$1,573
How this compares
$7,695 in reported general payments places this provider in the 90th percentile of 7,675 internal medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 97 | $137,139 |
| OzempicSemaglutide | 133 | $131,876 |
| EliquisApixaban | 68 | $73,412 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 54 | $48,693 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 35 | $39,463 |
| Tresiba Flextouch U-200Insulin Degludec | 19 | $28,897 |
| XareltoRivaroxaban | 14 | $21,209 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 23 | $17,115 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 16 | $16,351 |
| JardianceEmpagliflozin | 14 | $15,534 |
| EntrestoSacubitril/Valsartan | 17 | $15,250 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 15 | $14,849 |
| JanuviaSitagliptin Phosphate | 14 | $14,275 |
| LinzessLinaclotide | 16 | $12,232 |
| Repatha SureclickEvolocumab | 17 | $9,975 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $38 | $137,13997 claims |
| Novo NordiskOzempic | $172 | $131,876133 claims |
| PfizerEliquis | $102 | $73,41268 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $20 | $39,46335 claims |
| GSKTrelegy Ellipta, Shingrix | $103 | $20,55335 claims |
| NovartisEntresto | $166 | $15,25017 claims |
| AstraZenecaBreztri Aerosphere | $92 | $14,84915 claims |
| AbbVieLinzess | $526 | $12,23216 claims |
| Astellas Pharma US IncMyrbetriq | $195 | $9,84511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,675 internal medicine providers in Texas.
Other internal medicine in Odessa
- Suresh PrasadOdessa$90K
- Spencer BerthelsenSugar Land$891K
- Hameed AliTemple$773K
- Marc TribbleDallas$693K
- Gary SinclairDallas$599K
- Mohammed Al-NajjarEl Paso$586K
- Han SchmidlyDallas$465K
- Hussein TawbiHouston$365K
- Hans LeeHouston$327K
- Tapan KadiaHouston$311K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.